Annovis Bio Inc

Market Cap

$77M

Healthcare·Biotechnology·🇺🇸 United States·NYSE

Healthcare·Biotechnology·🇺🇸·NYSE

Stock Price

$1.80-$1.85 (-50.68%)

Jul 15, 2026

52W High $5.1052W Low $1.59

Company Details

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in o...

Leadership

Maria L. Maccecchini Ph.D.Founder

Founder, Acting CFO, CEO, President & Executive Director

Cheng Fang Ph.D.

Senior Vice President of Research & Development

Eve M. Damiano M.S., RAC

Senior Vice President of Regulatory Operations

Blake Jensen M.B.A.

Head of Quality

Hilda Maibach

Senior Vice President of Statistics

IPO Date

Feb 12, 2010

Website

www.annovisbio.com

Key Metrics TTM

Revenue

- YoY

Net Income

-$41M

EPS (Diluted)

Free Cash Flow

-$9.0B

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Revenue & Profitability

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee